Elicitation of mucosal immune responses against HIV
引发针对 HIV 的粘膜免疫反应
基本信息
- 批准号:9539522
- 负责人:
- 金额:$ 48.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-26 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAnimalsAntibody AvidityAntibody ResponseAntibody titer measurementAntigen PresentationAntigen-Presenting CellsAntigensArtificial nanoparticlesAvidityB-LymphocytesCD8-Positive T-LymphocytesCross PresentationCross-PrimingDataEbola virusEngineeringGastrointestinal tract structureGlycoproteinsGoalsHIVHIV-1HIV-1 vaccineHelper-Inducer T-LymphocyteImmune responseImmunityImmunizationImmunoglobulin GInfectionLipaseLipidsModelingMucosal Immune ResponsesMucosal ImmunityMucous MembraneMusOnionsOryctolagus cuniculusOutcomePlasmodium vivaxPropertyProtein SubunitsPublic HealthResearchSafetySeriesSerumStructure of germinal center of lymph nodeStructure-Activity RelationshipSystemT cell responseT-LymphocyteTechnologyTestingVaccinationVesicleViralVirus Diseasesaluminum sulfateantigen-specific T cellsbasecervicovaginalcrosslinkcytotoxicdesignimmunogenicityin vivolymph nodesmucosal vaccinationnanoformulationnanoparticlenanovaccineneutralizing antibodynext generationnonhuman primatenovelnovel vaccinespathogenprototyperesponsesafety studyvaccination strategyvaccine deliveryvaccine developmentvector
项目摘要
Abstract
Human immunodeficiency virus (HIV) primarily enters the host and initiates infection through mucosal tissues.
Therefore, a vaccination strategy that can elicit cellular and humoral immune responses in mucosal tissues is
urgently needed. However, there is currently no approved adjuvant that can achieve robust levels of both T-cell
and antibody responses in mucosal tissues. Therefore, there is a critical need for an alternative, effective, and
safe strategy for mucosal vaccination. Our long-range goal is to develop vaccine delivery systems that can
elicit protective immunity against HIV-1. Our objective here is to engineer nanoparticles for mucosal delivery
of HIV-1 antigens and investigate their impact on elicitation of systemic and mucosal immune responses. To
that end, we have developed a new nanoparticle (NP) system that can elicit strong cytotoxic CD8+ T
lymphocyte (CTL) responses with subunit protein antigens. We show that these new vaccine NPs promote
antigen delivery to antigen-presenting cells in vivo, generate CTLs that disseminate to mucosal tissues,
including cervicovaginal and gastrointestinal tracts, and protect animals against viral infection. We also show
that NPs induce significantly higher antibody titers, lasting > 400 days in mice with greater avidity, durability,
and breadth, compared with conventional adjuvants on the market (e.g. alum or Montanide). Based on these
preliminary data, we propose to develop a new NP-based strategy for mucosal immunization against HIV-1.
We will test our central hypothesis that NPs incorporated with T and B-cell HIV-1 immunogens will elicit
concerted cellular and humoral immune responses in mucosal tissues. At the completion of the proposed
studies, we will have identified a new vaccination technology that can induce mucosal T and B cell responses
against HIV-1. These studies will accelerate HIV-1 vaccine development and advance our understanding of the
impact of vaccine delivery systems on mucosal immunity.
摘要
人类免疫缺陷病毒(HIV)主要通过粘膜组织进入宿主并引发感染。
因此,一种可以在粘膜组织中诱导细胞和体液免疫反应的疫苗接种策略是
急需之物。然而,目前还没有批准的佐剂可以达到这两种T细胞的强劲水平
以及粘膜组织中的抗体反应。因此,迫切需要一种替代、有效和
粘膜疫苗接种的安全策略。我们的长期目标是开发能够
诱导对HIV-1的保护性免疫。我们的目标是设计用于粘膜递送的纳米颗粒
并研究其对系统和粘膜免疫反应的影响。至
为此,我们开发了一种新的纳米颗粒(NP)系统,可以诱导出强大的细胞毒性CD8+T细胞
淋巴细胞(CTL)对亚单位蛋白抗原的反应。我们发现这些新的疫苗NPs能促进
将抗原递送到体内的抗原提呈细胞,产生CTL并传播到粘膜组织,
包括宫颈、阴道和胃肠道,并保护动物免受病毒感染。我们还展示了
NPs能显著提高小鼠的抗体效价,可持续400天,具有更强的亲和力,耐受性,
与市场上的常规佐剂(如明矾或蒙太尼)相比,它具有更大的广度和广度。基于这些
根据初步数据,我们建议开发一种新的基于NP的黏膜免疫策略来对抗HIV-1。
我们将检验我们的中心假设,即与T和B细胞HIV-1免疫原结合的NPs将诱导
粘膜组织中的协同细胞和体液免疫反应。在完成建议的
研究表明,我们将发现一种新的疫苗接种技术,可以诱导粘膜T和B细胞反应
对抗HIV-1。这些研究将加速HIV-1疫苗的开发,并增进我们对
疫苗投放系统对粘膜免疫的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James J Moon其他文献
BATF2 suppresses cancer initiation by promoting γδ T-cell-mediated immunity
BATF2 通过促进 γδ T 细胞介导的免疫来抑制癌症发生
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Wang Gong;Hulya Taner;Yuesong Wu;Wanqing Cheng;Kohei Okuyama;Zaiye Li;Shadmehr Demehri;Felipe Nor;Deepak Nagrath;Steven B Chinn;Christopher R Donnelly;James J Moon;Yuying Xie;Yu Leo Lei - 通讯作者:
Yu Leo Lei
James J Moon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James J Moon', 18)}}的其他基金
Biomaterials for modulating the gut microbiome for immune activation
用于调节肠道微生物组以激活免疫的生物材料
- 批准号:
10614059 - 财政年份:2022
- 资助金额:
$ 48.94万 - 项目类别:
T cell Tolerance to Enteric Commensal Bacteria
T 细胞对肠道共生细菌的耐受性
- 批准号:
10608196 - 财政年份:2021
- 资助金额:
$ 48.94万 - 项目类别:
T cell Tolerance to Enteric Commensal Bacteria
T 细胞对肠道共生细菌的耐受性
- 批准号:
10299254 - 财政年份:2021
- 资助金额:
$ 48.94万 - 项目类别:
T cell Tolerance to Enteric Commensal Bacteria
T 细胞对肠道共生细菌的耐受性
- 批准号:
10424555 - 财政年份:2021
- 资助金额:
$ 48.94万 - 项目类别:
Elicitation of mucosal immune responses against HIV
引发针对 HIV 的粘膜免疫反应
- 批准号:
9292510 - 财政年份:2016
- 资助金额:
$ 48.94万 - 项目类别:
Elicitation of mucosal immune responses against HIV
引发针对 HIV 的粘膜免疫反应
- 批准号:
9752434 - 财政年份:2016
- 资助金额:
$ 48.94万 - 项目类别:
Elicitation of mucosal immune responses against HIV
引发针对 HIV 的粘膜免疫反应
- 批准号:
9271737 - 财政年份:2016
- 资助金额:
$ 48.94万 - 项目类别:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
调整生物材料-免疫细胞相互作用治疗多形性胶质母细胞瘤
- 批准号:
9348653 - 财政年份:2016
- 资助金额:
$ 48.94万 - 项目类别:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
调整生物材料-免疫细胞相互作用治疗多形性胶质母细胞瘤
- 批准号:
9512575 - 财政年份:2016
- 资助金额:
$ 48.94万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 48.94万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 48.94万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 48.94万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 48.94万 - 项目类别:
Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
- 批准号:
23KK0126 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 48.94万 - 项目类别:
Training Grant